Advertisement

Topics

AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1

10:30 EDT 17 Apr 2018 | ecancermedicalscience

A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab, tested in patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, was well tolerated and had clinical activity according to preliminary...

Original Article: AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...